1. Home
  2. LRE vs KALA Comparison

LRE vs KALA Comparison

Compare LRE & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lead Real Estate Co. Ltd

LRE

Lead Real Estate Co. Ltd

N/A

Current Price

$1.38

Market Cap

17.2M

Sector

N/A

ML Signal

N/A

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.36

Market Cap

16.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LRE
KALA
Founded
2001
2009
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2M
16.1M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
LRE
KALA
Price
$1.38
$0.36
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
20.5K
534.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
41.50
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.35
52 Week High
$2.86
$20.58

Technical Indicators

Market Signals
Indicator
LRE
KALA
Relative Strength Index (RSI) 52.21 35.05
Support Level $1.34 $0.35
Resistance Level $1.57 $0.72
Average True Range (ATR) 0.10 0.04
MACD 0.01 0.01
Stochastic Oscillator 47.06 10.61

Price Performance

Historical Comparison
LRE
KALA

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: